The Bayer DNA-PK inhibitor, BAY-8400 , is an orally active and selective DNA-PK kinase inhibitor that synergistically enhances the efficacy of radiotherapeutics in xenograft models. The program started with a campaign to identify ATR inhibitors, which resulted in hits against ATR, ATM, and DNA-PK, all of which are of interest due to their [...]
< 1 minute read
Oct. 6, 2021
BAY-8400: An Oral Selective DNA-PK Kinase Inhibitor
BAY-8400
oral selective DNA-PK kinase inhibitor synergy with radiotherapy in model from library screen Journal of Medicinal Chemistry Bayer AG, Berlin, Germany